SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 2,810.00
+120.00 (4.46%)
Nov 20, 2025, 3:30 PM KST
SillaJen Revenue
SillaJen had revenue of 2.39B KRW in the quarter ending June 30, 2025, with 196.49% growth. This brings the company's revenue in the last twelve months to 6.37B, up 284.19% year-over-year. In the year 2024, SillaJen had annual revenue of 3.93B, down -0.33%.
Revenue (ttm)
6.37B
Revenue Growth
+284.19%
P/S Ratio
58.36
Revenue / Employee
129.94M
Employees
37
Market Cap
371.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93B | -12.90M | -0.33% |
| Dec 31, 2023 | 3.94B | -1.07B | -21.42% |
| Dec 31, 2022 | 5.01B | 4.76B | 1,870.95% |
| Dec 31, 2021 | 254.36M | -1.42B | -84.77% |
| Dec 31, 2020 | 1.67B | -7.40B | -81.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |